Literature DB >> 29180249

Tumor necrosis in radical prostatectomies with high-grade prostate cancer is associated with multiple poor prognostic features and a high prevalence of residual disease.

Andres M Acosta1, Mohamed R H Al Rasheed2, Garth H Rauscher3, Erica Vormittag2, Khin Su Mon2, Asma Sharif2, Andre Kajdacsy-Balla2, Gayatry Mohapatra4.   

Abstract

The Gleason grading system and the recently defined Grade Groups are strong, well-established predictors of outcome in prostate cancer. Each Gleason score, however, is the result of a sum of categories (Gleason patterns or GPs) that are intrinsically heterogeneous, as each individual pattern encompasses several tumor morphologies. Although the prognostic value of specific morphologic components of GP4 has recently been demonstrated, the significance of the different patterns of GP5 is largely unknown. We reviewed 344 consecutive prostatectomies performed at the Hospital of the University of Illinois at Chicago between 2011 and 2016 and selected 56 cases with primary or secondary GP5 with archival material available for review. Subsequently, we sorted the cases according to the presence or absence of tumor necrosis in invasive adenocarcinoma GP5-designated G5 (+N) and G5 (-N), respectively-for comparison of histopathologic and clinical characteristics. The GP5 (+N) group demonstrated higher prevalence of biochemical recurrence (P=.0006) and seminal vesicle invasion (P=.02), with a trend toward a higher frequency of lymph node metastases (P=.07) and multifocal surgical margin involvement (P=.09). Also, G5 (+N) patients showed higher preoperative prostate-specific antigen values (P=.005) and a larger percentage of submitted tissue involved by tumor (P<.0001). Our results show that GP5 with tumor necrosis is associated with poor prognostic histopathologic features and high rates of residual disease after prostatectomy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biochemical recurrence; Gleason; PSA; Prostate cancer; Tumor necrosis

Mesh:

Year:  2017        PMID: 29180249     DOI: 10.1016/j.humpath.2017.11.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target.

Authors:  Jiepei He; Yuhan Zhou; Hector M Arredondo Carrera; Alexandria Sprules; Ramona Neagu; Sayyed Amin Zarkesh; Colby Eaton; Jian Luo; Alison Gartland; Ning Wang
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

2.  Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference.

Authors:  Constantinos Zamboglou; Montserrat Carles; Tobias Fechter; Selina Kiefer; Kathrin Reichel; Thomas F Fassbender; Peter Bronsert; Goeran Koeber; Oliver Schilling; Juri Ruf; Martin Werner; Cordula A Jilg; Dimos Baltas; Michael Mix; Anca L Grosu
Journal:  Theranostics       Date:  2019-04-13       Impact factor: 11.556

3.  Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.

Authors:  Geert J L H van Leenders; Esther I Verhoef; Eva Hollemans
Journal:  Histopathology       Date:  2020-09-13       Impact factor: 5.087

Review 4.  More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.

Authors:  Anniina Hyväkkä; Verneri Virtanen; Jukka Kemppainen; Tove J Grönroos; Heikki Minn; Maria Sundvall
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

5.  Zeylenone represses the progress of human prostate cancer by downregulating the Wnt/β‑catenin pathway.

Authors:  Shaohua Zeng; Baoyi Zhu; Jun Zeng; Wenqi Wu; Chonghe Jiang
Journal:  Mol Med Rep       Date:  2018-10-17       Impact factor: 2.952

6.  Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.

Authors:  Tim Hansum; Eva Hollemans; Esther I Verhoef; Chris H Bangma; John Rietbergen; Susanne Osanto; Rob C M Pelger; Tom van Wezel; Henk van der Poel; Elise Bekers; Jozien Helleman; Sebastiaan Remmers; Geert J L H van Leenders
Journal:  Mod Pathol       Date:  2021-06-26       Impact factor: 7.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.